SC79

SC79, a unique specific and BBB permeable Akt activator, activates Akt in the cytosol and inhibits Akt membrane translocation. SC79 specifically binds to the PH domain of Akt^[1][2][3]. In Vitro:SC79 augmentes Akt phosphorylation at both the Thr308 and S473 sites^[1].
SC79 (10.96 μM) induces cytosolic phosphorylation of Akt. SC79 enhances IGF1-induced Akt phosphorylation in both serum-starved cells and cells grown in serum-rich medium^[1].
SC79 reduces neuronal excitotoxicity and prevents stroke-induced neuronal death. SC79 suppresses PHAKTM-GFP plasma membrane translocation^[1].
SC79 restores proliferation of BRAT1 knockdown cells, and reduces the production of superoxide in mitochondria of MitoSox positive cells^[2].
SC79 upregulates FLIPL/S expression and consequently suppresses caspase-8 activation^[5].
Note:
SC79 is unstable in solution state^[6]. It is recommended to freshly prepare in DMSO for preparation and use as needed. In Vivo:SC79 treatment, even at much high dose (0.4 mg/g of body weight), does not induce any detectable changes in body weight, survival rate, appearance, and behavior in mice^[1].
SC79 (10 mg/kg, i.p.) protects C57BL/6 mice from fas-induced fulminant hepatic failure^[4].
SC79 protects hepatocytes from TNFα-mediated apoptosis and mice from Gal/LPS-induced liver injury and damage^[5].